Hindware Limited v. Anil Kumar & Ors.

CS(COMM) 381/2023, I.A. 10912/2023, I.A. 10913/2023

In a significant development concerning trademark infringement, Hindware Limited successfully negotiated an amicable settlement with Defendant No. 1. The plaintiff agreed to drop its claim for damages provided that the defendant withdraws his pending trademark application and commits not to use the disputed mark 'HINDWARE' on his goods. This order marks a pragmatic resolution in the ongoing dispute.

Jurisdiction
India
Court
Delhi High Court - Orders
Case Number
CS(COMM) 381/2023, I.A. 10912/2023, I.A. 10913/2023
Judge(s)
Amit Bansal

Practitioner Note

This case demonstrates the evidentiary and procedural standards applied in patent matters before Delhi High Court - Orders. Understanding the court's reasoning in Hindware Limited vs Anil Kumar & Ors. is valuable context for structuring arguments or assessing risk in similar proceedings.

Related Cases

patentC.O. (COMM.IPD-TM) 111/2023, I.A. 4946/2023; CS(COMM) 142/2023, I.A. 4878/2023

Rexcin Pharmaceuticals P LtdvsRekin Pharma P Ltd & Anr.

The Delhi High Court addressed a complex trademark dispute between Rexcin Pharmaceuticals and Rekin Pharma concerning the similar corporate names 'REXCIN' and 'REKIN'. The court noted that while Rexcin holds registrations for 'REXCIN', they are not currently using it commercially, whereas Rekin has registered 'REKIN-SP' in Class 05. To resolve the conflict, the Court proposed a potential settlement where both parties could agree to restrict the use of the disputed term only as part of their corporate name, rather than as a trademark or trade name. Both counsels agreed to consult their clients on this proposal and were directed to consider mediation.

patentT(CMA)(PT) No.134 of 2023 (OA/01/2017/PT/CHN)

Genmab A/SvsAssistant Controller of Patents and Designs, Government of India

Genmab A/S appealed the rejection of its patent application (No. 4718/CHENP/2007) for a monoclonal antibody targeting human CD38. The respondent argued that the antibody was merely a discovery of a naturally existing molecule, thus ineligible under Section 3(c). The High Court set aside the rejection, finding that the antibody was produced through substantial human intervention and possessed inventive step.

patent(T)CMP(PT)/32/2023; (T)CMA(PT)/SR.212/2023; (OA/SR.196/2015/PT/CHN

The University of HoustonvsThe Assistant Controller of Patents and Designs, Government of India

The University of Houston filed a Transfer Civil Miscellaneous Appeal seeking to set aside an earlier order and allow its patent application (No. 379/CHENP/2008) to proceed for grant. The petitioner subsequently endorsed that it did not intend to prosecute the appeal, leading the court to dismiss the petition.

patentCS (COMM) 427/2021

Chugai Seiyaku Kabushiki Kaisha & Anr.vsNatco Pharma Limited

Plaintiffs (Chugai Seiyaku Kabushiki Kaisha & Anr.) filed a suit seeking permanent injunction against Natco Pharma Limited for infringing Indian Patent No. 294424, which covers the tetracyclic compound Alectinib (Alecensa®). The dispute centered on the Defendant's alleged export and potential commercial launch of generic Alectinib products. The matter was amicably resolved.

patentCS(COMM) 103/2024

Sequoia Capital Operations Llc & OrsvsJohn Doe And Others

In this trademark infringement suit, the Delhi High Court addressed an application seeking to involve WhatsApp LLC in the proceedings. The court allowed WhatsApp's impleadment and issued specific directions requiring the platform to remove or block identified infringing groups and accounts associated with Sequoia Capital's trademarks. Crucially, while ordering the removal of known infringers, the court also mandated that Plaintiffs must first notify account holders before any further blocking action is taken, balancing enforcement needs with due process concerns.

Arctic Invent — IP Strategy

Dealing with a patent challenge?

Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.

Talk to our patent team →

Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.

Strategy Consult

Facing a similar patent matter?

Arctic's litigation team uses precedent data like this to build winning arguments.

Get a Strategy Call